Does a potent steroid cream cause fluid retention? new study investigates
NCT ID NCT02360202
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study measured fluid retention in 30 people with bullous pemphigoid who were treated with a strong steroid cream (clobetasol propionate). Researchers used bioimpedance to track changes in body water over 30 days. The goal was to understand if the cream causes fluid buildup and whether dietary changes like salt restriction might be helpful.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- clobetasol propionate cream
- What this could lead to
- If successful, this could clarify whether a salt-free diet is needed during treatment with strong topical steroids for bullous pemphigoid.
- What could go wrong
- This is a small, completed Phase 4 study with only 30 participants, so results may not apply broadly. It measures fluid changes, not treatment effectiveness or safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
30 people
The number who actually took part.
- Started
-
Feb 2015
- Finished
-
Feb 2017
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient with age higher than 18 * Patient with bullous pemphigoid, * Patient treated by local corticosteroid therapy (clobetasol propionate cream) but not yet processed or for less than 48 hours, * Signed informed consent. * Patient affiliated to Social Security Regimen * Effective contraception in women of childbearing age (for postmenopausal women, confirmatory diagnosis of menopause will be collected) Exclusion Criteria: * Concomitant treatment with corticosteroids * Recent introduction or recent (\<6 weeks) treatment with diuretics, angiotensin-converting enzyme, receptor antagonist or anti-angiotensin renin (aliskiren) * contraindication to the use of Clobetasol propionate (DERMOVAL and CLARELUX) * Patient on salt diet (\<or = to 5 g / d) * Patients carry a defibrillator or a pace maker * Amputated Patient * Pregnant and lactating * Patient with Urinary Incontinency * Recent heart decompensation in the last 6 weeks * known Nephrotic Syndrome * known or Severe hepatic impairment * Hypoalbuminaemia less than 20 g / l
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bullous pemphigoid are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rouen University Hospital
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Study reveals bone risks from common skin treatment
- Scientists probe hidden clot risks in autoimmune skin disorders
- New study tests easier treatment for blistering skin disease
- One-Dose hope for blistering skin disease?
- New antibody treatment offers hope for rare blistering skin disease
- Researchers track blistering skin disease to pave way for better treatments